- Home
- EQ vs SRZN Comparison
EQ vs SRZN Comparison
Compare EQ & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- SRZN
- Stock Information
- Founded
- EQ 2017
- SRZN 2015
- Country
- EQ United States
- SRZN United States
- Employees
- EQ N/A
- SRZN N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- EQ Health Care
- SRZN Health Care
- Exchange
- EQ Nasdaq
- SRZN Nasdaq
- Market Cap
- EQ 85.1M
- SRZN 97.3M
- IPO Year
- EQ 2018
- SRZN N/A
- Fundamental
- Price
- EQ $1.34
- SRZN $13.77
- Analyst Decision
- EQ Hold
- SRZN Strong Buy
- Analyst Count
- EQ 2
- SRZN 2
- Target Price
- EQ $1.00
- SRZN $38.50
- AVG Volume (30 Days)
- EQ 725.3K
- SRZN 32.4K
- Earning Date
- EQ 11-12-2025
- SRZN 11-05-2025
- Dividend Yield
- EQ N/A
- SRZN N/A
- EPS Growth
- EQ N/A
- SRZN N/A
- EPS
- EQ N/A
- SRZN N/A
- Revenue
- EQ $16,553,000.00
- SRZN $12,621,000.00
- Revenue This Year
- EQ N/A
- SRZN N/A
- Revenue Next Year
- EQ N/A
- SRZN N/A
- P/E Ratio
- EQ N/A
- SRZN N/A
- Revenue Growth
- EQ N/A
- SRZN N/A
- 52 Week Low
- EQ $0.27
- SRZN $5.90
- 52 Week High
- EQ $2.35
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- EQ 43.10
- SRZN 69.09
- Support Level
- EQ $1.41
- SRZN $13.28
- Resistance Level
- EQ $1.64
- SRZN $14.15
- Average True Range (ATR)
- EQ 0.11
- SRZN 0.67
- MACD
- EQ -0.02
- SRZN 0.08
- Stochastic Oscillator
- EQ 9.11
- SRZN 64.66
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).